TRACON Pharmaceuticals to Host Key Opinion Leader Webinar on Envafolimab for the Treatment of Sarcoma

NEXT STORY
Press release Oncology Venture acquires full ownership of its PARP inhibitor (2X-121) program
PREV STORY
ASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)

author_avatar
NASDAQ Market News

Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to Ridinilazole

Summit Therapeutics plc ("Summit" or the "Company") SUMMIT ENTERS INTO LICENCE AND COMMERCIALISATION AGREEMENT ...

author_avatar
NASDAQ Market News

Paratek Pharmaceuticals Generates Net Revenues of $2.0 Million in the Second Quarter of 2019

author_avatar
NASDAQ Market News